Joseph F. Merola - Concepedia

Author

Joseph F. Merola

Also Known As

J F Merola, J Merola, J. F. Merola, J. Merola, J.F Merola, J.F. Merola, JF Merola, JOSEPH F. MEROLA, Joe Merola, Joseph F Merola

720

Publications

12.2K

Citations

H-Index

120

Concepts

All Affiliations

Brigham and Women's Hospital Harvard University Icahn School of Medicine at Mount Sinai University of Pennsylvania University of Toronto

About

Joseph F. Merola is an author at Brigham and Women's Hospital specializing in dermatology, medicine, and psoriatic arthritis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	51	2.1K
2	Public Health	9	9	171
3	Allergy	4	4	131
4	Health Sciences	1	1	29
5	Social Sciences	1	1	25

Joseph F. Merola

145

Publications

7.1K

Citations

H-Index

Page 1

	Year	Citations
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis Philip J. Mease, Stephen Hall, Oliver FitzGerald, New England Journal of Medicine	2017	536
2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis Jasvinder A. Singh, Gordon Guyatt, Alexis Ogdie, Arthritis & Rheumatology	2018	465
Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus Richard Furie, Victoria P. Werth, Joseph F. Merola, Journal of Clinical Investigation	2019	286
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial Kristian Reich, Kim Papp, Andrew Blauvelt, The Lancet Systemic TreatmentClinical TrialsBimekizumab Versus UstekinumabPlaque PsoriasisBe Vivid	2021	276
Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis Iain B. McInnes, J. Anderson, Marina Magrey, New England Journal of Medicine	2021	276
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial Kim Papp, Joseph F. Merola, Alice B. Gottlieb, Journal of the American Academy of Dermatology	2018	187
A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process Linnea Thorlacius, John R Ingram, Bente Villumsen, British Journal of Dermatology	2018	165
Antibiotic or silver versus standard ventriculoperitoneal shunts (BASICS): a multicentre, single-blinded, randomised trial and economic evaluation Conor Mallucci, Michael D. Jenkinson, Elizabeth J. Conroy, The Lancet	2019	153
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE) Joseph F. Merola, Robert Landewé, Iain B. McInnes, The Lancet	2022	149
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL) Iain B. McInnes, Akihiko Asahina, Laura C. Coates, The Lancet	2022	146

Page 1